These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19596876)

  • 1. In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
    Osborne CS; Neckermann G; Fischer E; Pecanka R; Yu D; Manni K; Goldovitz J; Amaral K; Dzink-Fox J; Ryder NS
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3777-81. PubMed ID: 19596876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
    Andes D; van Ogtrop ML; Peng J; Craig WA
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
    Credito K; Lin G; Ednie LM; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4033-6. PubMed ID: 15388473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.
    Hilliard JJ; Fernandez J; Melton J; Macielag MJ; Goldschmidt R; Bush K; Abbanat D
    Antimicrob Agents Chemother; 2009 May; 53(5):2028-33. PubMed ID: 19273686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
    Ednie LM; Pankuch G; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4027-32. PubMed ID: 15388472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.
    Keel RA; Tessier PR; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4403-7. PubMed ID: 22687504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.
    LaPlante KL; Leonard SN; Andes DR; Craig WA; Rybak MJ
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2156-62. PubMed ID: 18411321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.
    Fonseca-Aten M; Salvatore CM; Mejías A; Ríos AM; Chávez-Bueno S; Katz K; Gómez AM; McCracken GH; Hardy RD
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4128-36. PubMed ID: 16189089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.
    Jacqueline C; Navas D; Batard E; Miegeville AF; Le Mabecque V; Kergueris MF; Bugnon D; Potel G; Caillon J
    Antimicrob Agents Chemother; 2005 Jan; 49(1):45-51. PubMed ID: 15616274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae.
    Choi S; Im W; Bartizal K
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4713-7. PubMed ID: 22713339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Resistance to linezolid in Staphylococcus aureus before its release].
    Akpabie A; Naga H; Giraud K; Al Rahiss R; Nadai S
    Pathol Biol (Paris); 2004 Oct; 52(8):493-6. PubMed ID: 15465271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.
    Banevicius MA; Kaplan N; Hafkin B; Nicolau DP
    J Chemother; 2013 Feb; 25(1):26-31. PubMed ID: 23433441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media.
    Humphrey WR; Shattuck MH; Zielinski RJ; Kuo MS; Biermacher JJ; Smith DP; Jensen JL; Schaadt RD; Zurenko GE; Richards IM
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1355-63. PubMed ID: 12654670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
    Manfredi R
    Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.
    Ford CW; Hamel JC; Wilson DM; Moerman JK; Stapert D; Yancey RJ; Hutchinson DK; Barbachyn MR; Brickner SJ
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1508-13. PubMed ID: 8726028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Linezolid--novel antibiotic for the treatment of gram-positive bacterial infections].
    Jankowski A; Stefanik W
    Wiad Lek; 2006; 59(9-10):727-31. PubMed ID: 17338140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.
    Vidaillac C; Parra-Ruiz J; Winterfield P; Rybak MJ
    Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
    Jacqueline C; Asseray N; Batard E; Le Mabecque V; Kergueris MF; Dube L; Bugnon D; Potel G; Caillon J
    Int J Antimicrob Agents; 2004 Oct; 24(4):393-6. PubMed ID: 15380267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linezolid: a review of its use in the management of serious gram-positive infections.
    Perry CM; Jarvis B
    Drugs; 2001; 61(4):525-51. PubMed ID: 11324682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.